FULC Valuation
Fulcrum Therapeutics Inc
$
6.510
- Overview
- Forecast
- Valuation
FULC Relative Valuation
FULC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, FULC is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for FULC's competitors is 2.30, providing a benchmark for relative valuation. Fulcrum Therapeutics Inc Corp (FULC) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
LRMR
Larimar Therapeutics Inc
2.060
USD
+5.91%
MRT
Marti Technologies Inc
2.950
USD
-7.23%
FDMT
4D Molecular Therapeutics Inc
3.850
USD
+1.32%
AOUT
American Outdoor Brands Inc
11.760
USD
-5.08%
KVAC
Keen Vision Acquisition Corp
11.320
USD
+0.18%
FUNC
First United Corp
31.340
USD
+0.10%
EVC
Entravision Communications Corp
1.880
USD
-2.08%
LFMD
LifeMD Inc
10.640
USD
+0.57%
ACB
Aurora Cannabis Inc
5.340
USD
+6.37%
LCNB
LCNB Corp
15.180
USD
-1.24%
FAQ
Is Fulcrum Therapeutics Inc (FULC) currently overvalued or undervalued?
Fulcrum Therapeutics Inc (FULC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 55.29. The fair price of Fulcrum Therapeutics Inc (FULC) is between to according to relative valuation methord.
What is Fulcrum Therapeutics Inc (FULC) fair value?
How does FULC's valuation metrics compare to the industry average?
What is the current P/B ratio for Fulcrum Therapeutics Inc (FULC) as of May 21 2025?
What is the current FCF Yield for Fulcrum Therapeutics Inc (FULC) as of May 21 2025?
What is the current Forward P/E ratio for Fulcrum Therapeutics Inc (FULC) as of May 21 2025?